Non-canonical transcriptional regulation of the poor prognostic factor UGT2B17 in chronic lymphocytic leukemic and normal B cells

• Published in: BMC cancer 2024-04, Vol.24 (1), p.410-410, Article 410
• Main Authors: Rouleau, Michèle, Villeneuve, Lyne, Allain, Eric P, McCabe-Leroux, Jules, Tremblay, Sophie, Nguyen Van Long, Flora, Uchil, Ashwini, Joly-Beauparlant, Charles, Droit, Arnaud, Guillemette, Chantal
• Format: Article
• Language: English
• Subjects: Alternative promoter; Apoptosis; Binding sites; Cells; Chromatin; Chronic lymphocytic leukemia; Disease resistance; Drug resistance; Electrophoretic mobility; Enzymes; Exons; Gene regulation; Genomics; Glucuronosyltransferase - genetics; Glycosyltransferase; Humans; Interferon regulation factors IRF; Interferon regulatory factor; Intestine; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemic B cells; Liver; Lymphocytes B; Minor Histocompatibility Antigens; Mutagenesis; Mutation; NF-kappa B - metabolism; NF-κB; NF-κB protein; Patients; Prognosis; Prostate; Proteins; Ribonucleic acid; RNA; RNA polymerase; STAT3; Stat3 protein; Transcription factors; Transcriptomes; Yeast
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-024-12143-7

High expression of the glycosyltransferase UGT2B17 represents an independent adverse prognostic marker in chronic lymphocytic leukemia (CLL). It also constitutes a predictive marker for therapeutic response and a drug resistance mechanism. The key determinants driving expression of the UGT2B17 gene in normal and leukemic B-cells remain undefined. The UGT2B17 transcriptome is complex and is comprised of at least 10 alternative transcripts, identified by previous RNA-sequencing of liver and intestine. We hypothesized that the transcriptional program regulating UGT2B17 in B-lymphocytes is distinct from the canonical expression previously characterized in the liver. RNA-sequencing and genomics data revealed a specific genomic landscape at the UGT2B17 locus in normal and leukemic B-cells. RNA-sequencing and quantitative PCR data indicated that the UGT2B17 enzyme is solely encoded by alternative transcripts expressed in CLL patient cells and not by the canonical transcript widely expressed in the liver and intestine. Chromatin accessible regions (ATAC-Seq) in CLL cells mapped with alternative promoters and non-coding exons, which may be derived from endogenous retrotransposon elements. By luciferase reporter assays, we identified key cis-regulatory STAT3, RELA and interferon regulatory factor (IRF) binding sequences driving the expression of UGT2B17 in lymphoblastoid and leukemic B-cells. Electrophoretic mobility shift assays and pharmacological inhibition demonstrated key roles for the CLL prosurvival transcription factors STAT3 and NF-κB in the leukemic expression of UGT2B17. UGT2B17 expression in B-CLL is driven by key regulators of CLL progression. Our data suggest that a NF-κB/STAT3/IRF/UGT2B17 axis may represent a novel B-cell pathway promoting disease progression and drug resistance.